The current study assessed the effects of statin and CoQ10 supplement use on changes in cognitive functioning in the Wisconsin Registry for Alzheimer’s Prevention study.
Methods:
1,573 subjects were administered medical histories, the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), Wechsler Memory Scale, Logical Memory subtest, and the Trail Making Test, Parts A (TMT-A) and B (TMT-B) 3-4 times over 5-10 years.
Results:
Linear mixed models did not yield significant effects for statin or CoQ10 supplement use on changes in mental status, learning and memory, psychomotor speed, and cognitive flexibility.
Conclusions:
Statin and/or CoQ10 supplement use was not associated with neuropsychological test performance in the Wisconsin Registry for Alzheimer’s Prevention study.
BaiJWBouletGHalpernEM, et al.Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovasc Diabetol. 2016;15:14. https://doi-org.proxyse.uits.iu.edu/10.1186/s12933-015-0318-9
2.
ChouRDanaTBlazinaIDaegesMJeanneTL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–2024. https://doi-org.proxyse.uits.iu.edu/10.1001/jama.2015.15629
ChuCSTsengPTStubbsB, et al.Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8(1):5804.
5.
OttBRDaielloLADahabrehIJ, et al.Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348–358.
6.
SwigerKJManalacRJBlumenthalRSBlahaMJMartinSS. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–1221.
7.
ZambónDQuintanaMMataP, et al.Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med. 2010;123(3):267–274.
8.
LiGLarsonEBSonnenJA, et al.Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69(9):878–885.
LezakMHowiesonDBiglerETranelD. Neuropsychological Assessment—Fifth Edition. New York, NY: Oxford University Press; 2012.
11.
MironVERajasekharanSJarjourAAZamvilSSKennedyTEAntelJP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007;55(2):130–143.
12.
YousefAOFahadAAbdel MoneimAEMetwallyDMEl-KhadragyMFKassabRB. The neuroprotective role of coenzyme Q10 against lead acetate-induced neurotoxicity is mediated by antioxidant, anti-inflammatory and anti-apoptotic activities. Int J Environ Res Public Health. 2019;16(16):2895. https://doi-org.proxyse.uits.iu.edu/10.3390/ijerph16162895
13.
DumontMKipianiKYuF, et al.Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer’s disease. J Alzheimer’s Dis. 2011;27(1):211–223.
14.
Hernández-CamachoJDBernierMLópez-LluchGNavasP. Coenzyme Q10 supplementation in aging and disease. Front Physiol. 2018;9:44. doi:10.3389/fphys.2018.00044
15.
WojsiatJZoltowskaKLaskowska-KaszubKWojdaU. Oxidant/antioxidant imbalance in Alzheimer’s disease: therapeutic and diagnostic prospects. Oxid Med Cell Longev. 2018;2018:6435861.
16.
StoughCNankivellMCamfieldDA, et al.CoQ10 and cognition a review and study protocol for a 90-day randomized controlled trial investigating the cognitive effects of ubiquinol in the healthy elderly. Front Aging Neurosci. 2019;11:103.
17.
JohnsonSCKoscikRLJonaitisEM, et al.The Wisconsin Registry for Alzheimer’s prevention: a review of findings and current directions. Alzheimers Dement (Amst).2017:10:130–142. doi:10.1101/206839
RadloffLS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.
20.
WechslerD. Wechsler Abbreviated Scale of Intelligence. New York, NY: The Psychological Corporation: Harcourt Brace & Company; 1997.
21.
FolsteinMFFolsteinSEMcHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
22.
WechslerD. Wechsler Adult Intelligence Scale—Revised. New York, NY: Harcourt Brace & CO. for the Psychological Corporation; 1981.
23.
SchmidtM. Rey Auditory Verbal Learning Test: A Handbook. Los Angeles, CA: Western Psychological Services; 1996.
24.
ReitanRM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–276.
25.
WechslerD. Wechsler Memory Scale—Revised. New York, NY: Harcourt Brace Jovanovich, Inc. for the Psychological Corporation; 1987.
26.
IBM. SPSS Statistics Version 26. Armonk, NY: IBM Corp; 2019.
27.
BenjaminiYYekutieliD. False discovery rate–adjusted multiple confidence intervals for selected parameters. J Am Stat Assoc. 2005;100(469):71–81.
28.
CorderoMDCotánDdel-Pozo-MartínY, et al.Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition. 2012;28(11-12):1200–1203.
29.
NachvakSMAlipourBMahdaviAM, et al.Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Clin Rheumatol. 2019;38(12):3367–3374.
30.
AbadFJSorrelMARománFJColomR. The relationships between WAIS-IV factor index scores and educational level: a bifactor model approach. Psychol Assess. 2016;28(8):987–1000. https://doi-org.proxyse.uits.iu.edu/10.1037/pas0000228
31.
NishitaYTangeCTomidaMAndoFShimokataH. Does high educational level protect against intellectual decline in older adults?; A 10-year longitudinal study. Jpn Psychol Res. 2013;55(4):378–389. doi:10.1111/jpr.12028
32.
WilsonRSHebertLEScherrPABarnesLLMendes de LeonCFEvansDA. Educational attainment and cognitive decline in old age. Neurology. 2009;72(5):460–465.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
